Adaptimmune Therapeutics Plc Return on Equity

Adaptimmune Therapeutics Plc's return on equity stands at 239.23%. That is above the Healthcare sector average of 13.26%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Adaptimmune Therapeutics Plc sits higher the Healthcare benchmark (13.26%) with a ROE of 239.23%. That is roughly 1703.7% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of 239.23% for Adaptimmune Therapeutics Plc means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Adaptimmune Therapeutics Plc's ROE evolved across reporting periods, while the comparison chart places ADAP next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, ROE is commonly used to spot outliers. Adaptimmune Therapeutics Plc's reading of 239.23% (sector avg 13.26%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.